Skip to main content

Developments in Molecular Testing and Biosimilars.

Publication ,  Journal Article
Winckworth-Prejsnar, K; Nardi, EA; Lentz, LK; Crawford, JA; Fitzgerald, CL; Carlson, RW
Published in: J Natl Compr Canc Netw
June 2017

Molecular testing and biosimilars offer the potential for increased access to targeted treatment options and reduction in healthcare costs, but come with significant challenges in ensuring patient access to innovation in cancer care while maintaining safe, effective, ethical, and affordable treatment options. As providers, payers, patients, and the larger healthcare systems become inundated with a wide variety of molecular diagnostics and an increased number of biosimilars coming to market, it will be important to understand regulatory guidance and policy implications relating to the appropriateness of molecular testing and the clinical use of biosimilars in cancer care. In September 2016, NCCN hosted the Molecular Testing and Biosimilars Policy Summit to address the challenges, issues, and opportunities in both the molecular testing and biosimilar landscapes. Keynote presentations and panelists further discussed the status and future of molecular testing and biosimilars within the oncology space, as well as patient access and education needs moving forward.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

June 2017

Volume

15

Issue

6

Start / End Page

772 / 782

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Molecular Diagnostic Techniques
  • Humans
  • Health Policy
  • Drug Discovery
  • Biosimilar Pharmaceuticals
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Winckworth-Prejsnar, K., Nardi, E. A., Lentz, L. K., Crawford, J. A., Fitzgerald, C. L., & Carlson, R. W. (2017). Developments in Molecular Testing and Biosimilars. J Natl Compr Canc Netw, 15(6), 772–782. https://doi.org/10.6004/jnccn.2017.0109
Winckworth-Prejsnar, Katy, Elizabeth A. Nardi, Lisa Korin Lentz, Jeffrey A. Crawford, C Lyn Fitzgerald, and Robert W. Carlson. “Developments in Molecular Testing and Biosimilars.J Natl Compr Canc Netw 15, no. 6 (June 2017): 772–82. https://doi.org/10.6004/jnccn.2017.0109.
Winckworth-Prejsnar K, Nardi EA, Lentz LK, Crawford JA, Fitzgerald CL, Carlson RW. Developments in Molecular Testing and Biosimilars. J Natl Compr Canc Netw. 2017 Jun;15(6):772–82.
Winckworth-Prejsnar, Katy, et al. “Developments in Molecular Testing and Biosimilars.J Natl Compr Canc Netw, vol. 15, no. 6, June 2017, pp. 772–82. Pubmed, doi:10.6004/jnccn.2017.0109.
Winckworth-Prejsnar K, Nardi EA, Lentz LK, Crawford JA, Fitzgerald CL, Carlson RW. Developments in Molecular Testing and Biosimilars. J Natl Compr Canc Netw. 2017 Jun;15(6):772–782.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

June 2017

Volume

15

Issue

6

Start / End Page

772 / 782

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Molecular Diagnostic Techniques
  • Humans
  • Health Policy
  • Drug Discovery
  • Biosimilar Pharmaceuticals
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis